1 completed, 1 unknown. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Unknown 1 |
| Phase 2 | 2 | Completed 1, Unknown 1 |
Follow Tarveda Therapeutics: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PEN-866 in Patients With Advanced Solid Malignancies PEN-866 Sodium, fluorouracil, Folinic acid - Carcinoma, Endometrial Adenocarcinoma | Phase 1 / Phase 2 | Unknown | Tarveda Therapeutics | 340 | 2017-08-29 | 2022-02-17 |
| PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung Cancers PEN-221 - Neuroendocrine Tumors, Carcinoma, Small Cell Lung | Phase 1 / Phase 2 | Completed | Tarveda Therapeutics | 89 | 2016-12-08 | 2021-12-14 |
Small Cell Lung Carcinoma (2) · Anus Neoplasms (1) · Carcinoma (1) · Carcinoma, Neuroendocrine (1) · Carcinoma, Squamous Cell (1) · Neoplasms (1) · Neuroendocrine Tumors (1) · Stomach Neoplasms (1)
Fluorouracil (1) · Leucovorin (1) · niraparib (1)
United States (2) · United Kingdom (1)
Anish Thomas, MD (1)